{
  "ticker": "CC5",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973732",
  "id": "02973732",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250729",
  "time": "0933",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m7v81bt25245.pdf",
  "summary": "### **Clever Culture Systems Ltd (ASX: CC5) \u2013 Quarterly Report (Appendix 4C) Summary**  \n\n#### **Key Operational & Financial Highlights**  \n- **Customer Traction**:  \n  - **AstraZeneca**: 9 APAS\u00ae Independence units installed and in routine use globally.  \n  - **Novo Nordisk**: First order placed as part of group-wide evaluation for global manufacturing.  \n  - **Sales Pipeline**: $40m+ opportunity from 5 existing customers (60\u201380 instruments, $36\u201348m upfront sales, $7\u20139m annual recurring revenue).  \n- **Product Development**:  \n  - Contact plate analysis module (doubles APAS\u00ae capability) finalized for August 2025 launch.  \n- **Financials**:  \n  - **Cash Balance (30 Jun 2025)**: $1.3m.  \n  - **Expected Inflows (Next 2 Quarters)**: $3.8m (receivables, Novo Nordisk sale, R&D tax incentive).  \n  - **Net Cash Outflow (Quarter)**: $0.95m (incl. $0.3m for contact plate development).  \n- **Outstanding Options**: 397.5m listed options (ASX: CC5OA) exercisable at $0.008, expiring 15 Nov 2025 ($3.2m potential proceeds).  \n\n#### **Material Catalysts**  \n- Contact plate module launch (Sep 2025) to expand market adoption.  \n- Advanced discussions with additional top-tier pharma customers.  \n\n**No other material information identified.**",
  "usage": {
    "prompt_tokens": 6686,
    "completion_tokens": 335,
    "total_tokens": 7021,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-28T23:48:51.714907"
}